Case-Based Roundtable Meetings Spotlight: January 1, 2022

January 16, 2022

During a Targeted Oncology live event, John M. Pagel, MD, PhD, and participants discussed their experiences with BTK inhibitors such as acalabrutinib and ibrutinib in terms of efficacy and tolerability as well as other treatment options in patients with chronic lymphocytic leukemia.

January 16, 2022

During a Targeted Oncology live event, Aparna Hegde, MD, discussed the results of the KEYNOTE-189 study of pemetrexed and pembrolizumab, the KEYNOTE-042 study of single-agent pembrolizumab, and the CheckMate 227 study of nivolumab and ipilimumab in patients with non–small cell lung cancer.

January 15, 2022

During a Targeted Oncology live event, Grzegorz S. Nowakowski, MD, discussed the case of a patient treated with tafasitamab plus lenalidomide in the second line for diffuse B-cell lymphoma.

January 14, 2022

During a Targeted Oncology case-based virtual event, Jamile M. Shammo, MD, discussed testing, risk assessment, and therapy for patients with high-risk myelofibrosis.

January 14, 2022

During a Targeted Oncology Case-Based Roundtable event, Toni K. Choueiri, MD, discussed treatment options using immune checkpoint inhibitors in patients with advanced renal cell carcinoma.

January 13, 2022

During a Targeted Oncology Case-Based Roundtable event, Shilpa Gupta, MD, discussed new options for late-line therapies including FGFR inhibitors in patients with bladder cancer.

January 12, 2022

During a Targeted Oncology Case-Based Roundtable event, Mark A. Socinski, MD, discussed how to approach treating patients with lung cancer with rare mutations that can be targeted by certain treatments.

January 10, 2022

Twenty-two days following transplantation, a patient with graft-versus-host disease presented with new symptoms.

January 07, 2022

During a Targeted Oncology Case-Based Roundtable event, Chul Kim, MD, MPH, assistant professor at Georgetown University, discussed immunotherapy options for patients with non–small cell lung cancer with PD-L1 expression.